Low-Density Lipoprotein Cholesterol reduction reduces the risk of recurrent Myocardial Infarction and death in Coronary Artery Disease patients and in unhealthy individuals. Reduced levels of low-density lipoprotein also inhibit the development of coronary atherosclerosis. By preparing and encouraging patients to adhere to their pharmacotherapeutic regimens, dietary modifications, and management plans, clinical pharmacists can help to ensure that pharmacotherapy has beneficial results. It is clear that the initiatives to increase adherence and ongoing lipid-lowering medication use in high-risk patients are required. Long-term face-to-face counseling is necessary for effective care but may not be practical for many patients. A different stra...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Lifetime medication burden from current approaches to LDL-cholesterol (LDL-C) lowering is reliant on...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Lowering cholesterol levels is a primary approach for reducing the risk of coronary heart disease (C...
Bachground: Lipid-lowering drugs are effective preventive medication for patients at risk of cardiov...
H yperlipidemia and the atherosclerotic conditions that result from it are well recog-nized as major...
Lipid-lowering pharmacotherapy reduces morbidity andmortality caused by cardiovascular disease.1 How...
BACKGROUND: In the treatment of coronary heart disease, secondary prevention goals are still often u...
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified low d...
Poor lipid control is a risk factor for cardiovascular diseases and diabetes complications. Fre-quen...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Purpose - To describe medication adherence to lipid-lowering drugs (LLDs), antihypertensive drugs, a...
Background: Inadequate patient adherence to a medication regimen is a major factor in the lack of su...
Abstract Background In the treatment of coronary heart disease, secondary prevention goals are still...
BACKGROUND: Hyperlipidemia increases the risk of cardiovascular diseases, and control is pivotal for...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Lifetime medication burden from current approaches to LDL-cholesterol (LDL-C) lowering is reliant on...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Lowering cholesterol levels is a primary approach for reducing the risk of coronary heart disease (C...
Bachground: Lipid-lowering drugs are effective preventive medication for patients at risk of cardiov...
H yperlipidemia and the atherosclerotic conditions that result from it are well recog-nized as major...
Lipid-lowering pharmacotherapy reduces morbidity andmortality caused by cardiovascular disease.1 How...
BACKGROUND: In the treatment of coronary heart disease, secondary prevention goals are still often u...
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified low d...
Poor lipid control is a risk factor for cardiovascular diseases and diabetes complications. Fre-quen...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Purpose - To describe medication adherence to lipid-lowering drugs (LLDs), antihypertensive drugs, a...
Background: Inadequate patient adherence to a medication regimen is a major factor in the lack of su...
Abstract Background In the treatment of coronary heart disease, secondary prevention goals are still...
BACKGROUND: Hyperlipidemia increases the risk of cardiovascular diseases, and control is pivotal for...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Lifetime medication burden from current approaches to LDL-cholesterol (LDL-C) lowering is reliant on...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...